Reconsidering a “chopped liver”: The need for improving glomular filtration rate estimation for hepatic transplantation
Chirag R. Parikh, Justin M. Belcher – 27 January 2014
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real‐life practice
Hua Zhang, Calvin Q. Pan, Qiumei Pang, Ruihua Tian, Miaoe Yan, Xin Liu – 27 January 2014 – Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother‐to‐child transmission (MTCT) in real‐world settings. During the period of January 2009 to March 2011, we enrolled hepatitis B e antigen–positive mothers with HBV DNA >6 log10 copies/mL in China. At gestation week 28, the mothers received LdT or LAM until postpartum week 4 or no treatment (NTx). The study endpoints were the safety of LdT/LAM use and MTCT rates.
Duct‐to‐duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy
Michael E. Sutton, Rico D. Bense, Ton Lisman, Eric J. Jagt, Aad P. Berg, Robert J. Porte – 24 January 2014 – There is no consensus on the preferred type of biliary reconstruction for patients undergoing orthotopic liver transplantation (OLT) for primary sclerosing cholangitis (PSC). The aim of this study was to compare long‐term outcomes after OLT for PSC using either duct‐to‐duct anastomosis or Roux‐en‐Y hepaticojejunostomy for biliary reconstruction.
Fairly rare de novo inflammatory pseudotumor in a graft after living donor liver transplantation
Shohei Yoshiya, Toru Ikegami, Tomoharu Yoshizumi, Huanlin Wang, Noboru Harada, Yo‐Ichi Yamashita, Akihiro Nishie, Ken Shirabe, Yoshinao Oda, Yoshihiko Maehara – 23 January 2014
Liver and systemic insulin resistance
Nicolas Lanthier, Isabelle A. Leclercq – 22 January 2014
The COP9 signalosome is a repressor of replicative stress responses and polyploidization in the regenerating liver
Martina Panattoni, Laura Maiorino, Anna Lukacs, Lorena Zentilin, Davide Mazza, Francesca Sanvito, Giovanni Sitia, Luca G. Guidotti, Ruggero Pardi – 22 January 2014 – Aberrant DNA replication induced by deregulated or excessive proliferative stimuli evokes a “replicative stress response” leading to cell cycle restriction and/or apoptosis. This robust fail‐safe mechanism is eventually bypassed by transformed cells, due to ill‐defined epistatic interactions.
Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis
Edoardo G. Giannini, R. Todd Stravitz, Stephen H. Caldwell – 22 January 2014
Obeticholic acid: A new light in the shadows treating portal hypertension?
Jordi Gracia‐Sancho, Virginia Hernández‐Gea, Juan Carlos Garcia‐Pagán – 22 January 2014
Systems biology for hepatologists
José M. Mato, M. Luz Martínez‐Chantar, Shelly C. Lu – 21 January 2014 – Medicine is expected to benefit from combining usual cellular and molecular studies with high‐throughput methods (genomics, transcriptomics, proteomics, and metabolomics). These methods, collectively known as omics, permit the determination of thousands of molecules (variations within genes, RNAs, proteins, metabolites) within a tissue, cell, or biological fluid. The use of these methods is very demanding in terms of the design of the study, acquisition, storage, analysis, and interpretation of the data.
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response
Jacinta A. Holmes, Stuart K. Roberts, Rachel J. Ali, Gregory J. Dore, William Sievert, Geoffrey W. McCaughan, Darrell H. Crawford, Wendy S. Cheng, Martin D. Weltman, Sara Bonanzinga, Kumar Visvanathan, Vijaya Sundararajan, Paul V. Desmond, D. Scott Bowden, Gail V. Matthews, Alexander J. Thompson, on behalf of the CHARIOT Study Group – 21 January 2014 – On‐treatment anemia is associated with higher sustained virological response (SVR) rates during peginterferon plus ribavirin (RBV) therapy.